MedPath
HSA Approval

DOTAREM INJECTION 27.932 g/ 100 ml

SIN09008P

DOTAREM INJECTION 27.932 g/ 100 ml

DOTAREM INJECTION 27.932 g/ 100 ml

November 18, 1996

TRANSMEDIC PTE LTD

TRANSMEDIC PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantTRANSMEDIC PTE LTD
Licence HolderTRANSMEDIC PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

INJECTION

**4.2. Posology and method of administration** **Posology** Adults The recommended dose is 0.1 mmol/kg, i.e. 0.2 mL/kg, in adults. **Special populations** Impaired renal function The adult dose applies to patients with mild to moderate renal impairment (GFR ≥ 30 ml/min/1.73m2 ). Dotarem should only be used in patients with severe renal impairment (GFR < 30 ml/min/1.73m2 ) and in patients in the perioperative liver transplantation period after careful risk/benefit assessment and if the diagnostic information is essential and not available with non-contrast enhanced MRI (see section 4.4 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). If it is necessary to use Dotarem, the dose should not exceed 0.1 mmol/kg body weight. More than one dose should not be used during a scan. Because of the lack of information on repeated administration, Dotarem injections should not be repeated unless the interval between injections is at least 7 days. Elderly (aged 65 years and above) No dosage adjustment is considered necessary. Caution should be exercised in elderly patients (see section 4.4 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). Impaired hepatic function The adult dose applies to these patients. Caution is recommended, especially in the case of perioperative liver transplantation period. Paediatric population (2–18 years) _MRI of brain and spine / whole-body MRI:_ the recommended and maximum dose of Gadoteric acid is 0.1 mmol/kg body weight. More than one dose should not be used during a scan. **Method of administration** The product is indicated for intravenous administration only. Intravascular administration of contrast media should, if possible, be done with the patient lying down. After the administration, the patient should be kept under observation for at least half an hour, since experience shows that the majority of undesirable effects occur within this time. Paediatric population (2–18 years) Depending on the amount of gadoteric acid to be given to the child, it is preferable to use gadoteric acid vials with a single use syringe of a volume adapted to this amount in order to have a better precision of the injected volume. In infants the required dose should be administered by hand.

INTRAVENOUS

Medical Information

**4.1. Therapeutic indications** This medicinal product is for diagnostic use only. Nuclear magnetic resonance imaging: - Neuroradiology: tumour of the spine and the surrounding tissues, intracranial tumours. - Abdominal radiology: primary and secondary tumours. - Primary tumour of the bone and soft tissues.

**4.3. Contraindications** Hypersensitivity to gadoteric acid, to meglumine or to any medicinal products containing gadolinium.

V08CA02

gadoteric acid

Manufacturer Information

TRANSMEDIC PTE LTD

GUERBET

Active Ingredients

GADOTERIC ACID

27.932 g/ 100 ml

Gadoteric acid

Documents

Package Inserts

Dotarem PI.pdf

Approved: March 20, 2019

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

DOTAREM INJECTION 27.932 g/ 100 ml - HSA Approval | MedPath